# Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation

Study · id `cardio:ct-nct06871228` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06871228](<https://clinicaltrials.gov/study/NCT06871228>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06871228

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4100 participants.

## Technical summary

Registry record NCT06871228. Randomized; single masking; primary purpose treatment. Start 2025-08-05 (actual); primary completion 2029-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 4100 participants (planned count; ClinicalTrials.gov record NCT06871228, source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)
- Started: 2025-08-05 (actual) (ClinicalTrials.gov record NCT06871228, source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)
- Primary completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06871228, source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT06871228, source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06871228, source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06871228-2026-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation
- Acronym: DIAMOND-AF
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): NOAC discontinuation
- Intervention (Drug): NOAC continuation
- Intervention (Device): Smartwatch single-lead ECG monitoring
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 27fdbcf2a8da77df1e395d3ab765d0d0f146bc5fd563b6ad9d06f00867f945c9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
